The Future

Matti Vainio, ECHA & Anna Borràs Herrero, European Commission
with
France Capon (EPMF), Richard Luit (SEAC),
Finn Pedersen (DK), Dolores Romano (EEB) &
Martina Vosteen (Ramboll)

Alternatives and substitution

- Use desciption is considered often to be too broad:

  What could be done so that the uses are described in a meaningful manner?
  - What should applicants and alternative providers do? When?
  - What should regulators do (to support this)?
  - Would a ”negative list” (of ”sub-uses” not covered , be helpful?)

- To what extent is it possible to know all uses in advance?
- Concerns are voiced that the AfA process favours applicants to the detriment of alternative providers. How can this be addressed?

How can the authorisation process be more cost-effective?



Costs of applications have decreased over the years, as more experience has been gained.

- How could the costs of applying be reduced?
- Anything that ECHA/Commission could do?

Predictability

- How useful is the current guidance and support from ECHA for preparing robust applications and third party contributions?
- What is missing?

- How can the **supply chain communication** be further improved, both downstream (to inform and involve DUs) and upstream (to prepare robust upstream applications)?



How can the authorisation process be more cost-effective?